
Ask a doctor about a prescription for SITAGLIPTIN/METFORMIN VISO FARMACEUTICA 50 mg/850 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Sitagliptin/Metformin Viso Pharmaceutical 50 mg/850 mg film-coated tablets EFG
sitagliptin/metformin hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Sitagliptin/Metformin Viso Pharmaceutical contains two different medicines called sitagliptin and metformin.
They work together to control the levels of sugar in the blood in adult patients with a form of diabetes called “type 2 diabetes mellitus”. This medicine helps to increase the amounts of insulin produced after a meal and reduces the amount of sugar produced by your body.
Together with diet and exercise, this medicine helps you to lower your blood sugar level. This medicine can be used alone or with certain other medicines for diabetes (insulin, sulfonylureas, or glitazones).
What is type 2 diabetes?
Type 2 diabetes is a condition in which your body does not produce enough insulin and the insulin that your body produces does not work as well as it should. Your body may also produce too much sugar.
When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, such as heart diseases (cardiac), kidney diseases (renal), blindness, and amputations.
Do not take Sitagliptin/Metformin Viso Pharmaceutical
Do not take Sitagliptin/Metformin if you are affected by any of the above circumstances and consult your doctor about other ways to control your diabetes. If you are not sure, consult your doctor, pharmacist, or nurse before taking this medicine.
Warnings and precautions
There have been reports of pancreatitis in patients treated with Sitagliptin/Metformin (see section 4).
If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid.
Your doctor may ask you to stop taking Sitagliptin/Metformin.
Risk of lactic acidosis
Sitagliptin/Metformin can cause a very rare but very serious side effect called lactic acidosis, especially if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, severe infections, prolonged fasting, or alcohol intake, dehydration (see more information below), liver problems, and any medical condition in which a part of the body has a reduced supply of oxygen (such as acute and severe heart diseases).
If any of the above applies to you, consult your doctor for further instructions.
Consult your doctor immediately if:
Stop taking Sitagliptin/Metformin Viso Pharmaceutical for a short period if you have a condition that may be associated with dehydration(significant loss of body fluids) such as severe vomiting, diarrhea, fever, heat exposure, or if you drink less fluid than usual. Consult your doctor for further instructions.
Stop taking Sitagliptin/Metformin Viso Pharmaceutical and contact a doctor or the nearest hospital immediately if you experience any of the symptoms of lactic acidosis, as this condition can lead to coma.
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and must be treated in a hospital.
Consult your doctor or pharmacist before taking Sitagliptin/Metformin:
If you need to undergo major surgery, you must stop taking this medicine during the procedure and for some time after. Your doctor will decide when you should stop taking Sitagliptin/Metformin and when you can restart it.
If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.
During treatment with Sitagliptin/Metformin, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person and/or if your kidney function is worsening.
Children and adolescents
Children and adolescents under 18 years should not use this medicine. It is not effective in children and adolescents aged between 10 and 17 years. It is not known if this medicine is safe and effective when used in children under 10 years.
Other medicines and Sitagliptin/Metformin Viso Pharmaceutical
If you need to be given an injection of a contrast agent that contains iodine into your bloodstream, for example, in the context of a radiograph or scan, you must stop taking Sitagliptin/Metformin before the injection or at the time of the injection. Your doctor will decide when you should stop taking this medicine and when you can restart it.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of Sitagliptin/Metformin. It is especially important to mention the following:
Taking Sitagliptin/Metformin Viso Pharmaceutical with alcohol
Avoid excessive alcohol intake while taking Sitagliptin/Metformin, as this can increase the risk of lactic acidosis (see section “Warnings and precautions”).
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not take this medicine during pregnancy. Do not take this medicine if you are breastfeeding. See section 2, Do not take Sitagliptin/Metformin Viso Pharmaceutical.
Driving and using machines
The effect of this medicine on your ability to drive or use machines is negligible or non-existent. However, dizziness and drowsiness have been reported with sitagliptin, which may affect your ability to drive or use machines.
Taking this medicine with sulfonylureas or insulin may cause hypoglycemia, which may affect your ability to drive or use machines or work without a safe support.
Sitagliptin/Metformin Viso Pharmaceutical contains sodium
Sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medicine given by your doctor. In case of doubt, consult your doctor or pharmacist again.
You should continue with the diet recommended by your doctor during treatment with this medicine and be careful that your carbohydrate intake is evenly distributed throughout the day.
It is unlikely that treatment with this medicine alone will cause you to have low blood sugar (hypoglycemia). Low blood sugar can occur when this medicine is taken with a sulfonylurea or insulin, so your doctor may consider it necessary to reduce the dose of your sulfonylurea or insulin.
If you take more Sitagliptin/Metformin Viso Pharmaceutical than you should
If you take more than the prescribed dose of this medicine, contact your doctor immediately. Go to the hospital if you have symptoms of lactic acidosis such as feeling cold or unwell, nausea or severe vomiting, stomach pain, unexplained weight loss, muscle cramps, or rapid breathing (see section “Warnings and precautions”).
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Sitagliptin/Metformin Viso Pharmaceutical
If you forget to take a dose, take it as soon as you remember. If you do not remember until the time of your next dose, skip the missed dose and continue with your usual treatment. Do not take a double dose to make up for missed doses.
If you stop taking Sitagliptin/Metformin Viso Pharmaceutical
Continue taking this medicine for as long as your doctor tells you to, so that it can help you control your blood sugar levels. Do not stop taking this medicine without first talking to your doctor. If you stop taking Sitagliptin/Metformin, your blood sugar levels may increase again.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
STOP taking Sitagliptina/Metformina and go to the doctor immediately if you notice any of the following serious adverse effects:
Sitagliptina/Metformina may cause a very rare (may affect up to 1 in 10,000 people) but very serious adverse effect called lactic acidosis (see section "Warnings and Precautions"). If this happens to you, you must stop taking Sitagliptina/Metformina and contact a doctor or the nearest hospital immediately, as lactic acidosis can lead to coma.
If you have a severe allergic reaction (frequency not known), including skin rash, hives, blisters on the skin/desquamation of the skin, and swelling of the face, lips, tongue, and throat that can cause difficulty breathing or swallowing, stop taking this medicine and consult your doctor immediately. Your doctor may prescribe a medicine to treat the allergic reaction and a different medicine for the treatment of diabetes.
Some patients who took metformin have experienced the following adverse effects after starting treatment with sitagliptina:
Frequent (may affect up to 1 in 10 people): low blood sugar, nausea, gas, vomiting
Infrequent (may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, drowsiness
Some patients have experienced diarrhea, nausea, gas, constipation, stomach pain, or vomiting when starting treatment with the combination of sitagliptina and metformina (frequency classified as frequent).
Some patients have experienced the following adverse effects when taking this medicine with a sulfonylurea such as glimepiride:
Very frequent (may affect more than 1 in 10 people): low blood sugar levels
Frequent: constipation
Some patients have presented the following adverse effects while taking this medicine in combination with pioglitazone:
Frequent: swelling of hands or feet
Some patients have presented the following adverse effects while taking this medicine in combination with insulin:
Very frequent: low blood sugar levels
Infrequent: dry mouth, headache
Some patients have experienced the following adverse effects during clinical trials while taking sitagliptina alone (one of the medicines that contains Sitagliptina/Metformina) or during use after the approval of Sitagliptina/Metformina or sitagliptina alone or with other diabetes medicines:
Frequent: low blood sugar, headache, upper respiratory tract infection, nasal congestion or nasal discharge, and sore throat, arthrosis, pain in the arm or leg
Infrequent: dizziness, constipation, itching
Rare: reduction in platelet count
Frequency not known: kidney problems (which may require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)
Some patients have experienced the following adverse effects while taking metformin alone:
Very frequent: nausea, vomiting, diarrhea, stomach pain, and loss of appetite. These symptoms may appear when you start taking metformin and usually disappear.
Frequent: metallic taste, decreased or low vitamin B12 levels in blood (symptoms may include extreme fatigue, pain, and redness of the tongue, tingling, or pale or yellowish skin). Your doctor may request tests to determine the cause of your symptoms because some of them may also be caused by diabetes or other unrelated health problems.
Very rare: hepatitis (a liver problem), hives, skin redness (rash), or itching
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the blister pack and on the container after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30 °C.
Medicines should not be thrown down the drain or into the trash. Deposit the containers and medicines you no longer need in the SIGRE Point of the pharmacy. Ask your pharmacist how to dispose of the containers and medicines you no longer need. This way, you will help protect the environment.
Composition of Sitagliptina/Metformina Viso Farmacéutica
Sitagliptina/Metformina Viso Farmacéutica 50 mg/850 mg film-coated tablets: Each tablet contains 50 mg of sitagliptina (as monohydrate hydrochloride) and 850 mg of metformina hydrochloride.
Core of the tablet: microcrystalline cellulose, povidone (K29/32), sodium lauryl sulfate, and magnesium stearate.
Coating (50 mg/850 mg): PVA-PEG graft copolymer (E1209), talc, titanium dioxide, GMDCC (Glyceryl Mono and dicaprylate caprate), GMCC (Glyceryl monocaprylate caprate) Type 1, mono/diglycerides, glycerol, poly(vinyl alcohol), and red iron oxide.
Appearance of the Product and Package Contents
Sitagliptina/Metformina Viso Farmacéutica 50 mg/850 mg film-coated tablets: Film-coated tablets, oval, biconvex, approximately 20.5 mm x 9.5 mm, pink, engraved with "S476" on one side and smooth on the other.
Sitagliptina/Metformina Viso Farmacéutica 50 mg/850 mg film-coated tablets are packaged in
It is possible that only some package sizes are marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Glenmark Arzneimittel GmbH
Industriestr. 31
82194 Gröbenzell
Germany
Manufacturer:
LABORATORIOS LICONSA S.A.
Avda. Miralcampo, Nº 7
Polígono Industrial Miralcampo
19200 Azuqueca de Henares (Guadalajara)
Spain
You can request more information about this medicine by contacting the local representative of the Marketing Authorization Holder:
Glenmark Farmacéutica, S.L.U.
C/ Retama 7, 7ª planta
28045 Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area with the following names:
Country | Name |
Germany | Sitagliptin/Metformin Glenmark 50 mg/850 mg Filmtabletten |
Denmark | Sitagliptin/Metformin Glenmark |
Spain | Sitagliptina/Metformina Viso Farmacéutica 50 mg/850 mg film-coated tablets EFG |
Czech Republic | Sitagliptin/Metformin Glenmark |
Finland | Sitagliptin/Metformin Glenmark 50 mg/850 mg tablets, film-coated |
Norway | Sitagliptin/Metformin Glenmark 50 mg/850 mg film-coated tablets |
Sweden | Sitagliptin/Metformin Glenmark 50 mg/850 mg film-coated tablets |
Slovakia | Sitagliptin/Metformin Glenmark 50 mg/850 mg |
Date of the last revision of this prospectus:April 2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of SITAGLIPTIN/METFORMIN VISO FARMACEUTICA 50 mg/850 mg FILM-COATED TABLETS in November, 2025 is around 27.32 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for SITAGLIPTIN/METFORMIN VISO FARMACEUTICA 50 mg/850 mg FILM-COATED TABLETS – subject to medical assessment and local rules.